ImmunityBio (IBRX) Stock Price, News & Analysis

Company Overview

ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator. In 2024, the U.S. Food and Drug Administration approved ANKTIVA in combination with Bacillus Calmette-Guérin for adults with non-muscle-invasive bladder cancer that is unresponsive to BCG and includes carcinoma in situ, with or without papillary tumors. ImmunityBio is also evaluating ANKTIVA and other investigational therapies in additional cancer settings.

ImmunityBio was founded by physician and entrepreneur Patrick Soon-Shiong and is headquartered in the United States. The company’s research and clinical development activities have included collaborations and trials involving patients in multiple countries. Its leadership has included Soon-Shiong as executive chairman and global chief medical officer, with Richard Adcock serving as president and chief executive officer.

Key Stats

• Today's Range: $10.13 to $10.81
• 50-Day Range: $6.83 to $10.28
• 52-Week Range: $1.95 to $12.43
• Volume: 16.79 million shs
• Average Volume: 20.79 million shs
• Market Capitalization: $11.00 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.20
• Consensus Rating: Moderate Buy

ImmunityBio Stock Analysis - MarketRank™

ImmunityBio scored higher than 52% of companies evaluated by MarketBeat, and ranked 472nd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ImmunityBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

ImmunityBio has a consensus price target of $14.20, representing about 36.8% upside from its current price of $10.38.

Amount of Analyst Coverage

ImmunityBio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ImmunityBio are expected to grow in the coming year, from ($0.44) to ($0.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmunityBio is -10.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmunityBio is -10.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

34.91% of the float of ImmunityBio has been sold short.

Short Interest Ratio / Days to Cover

ImmunityBio has a short interest ratio ("days to cover") of 15.86, which indicates bearish sentiment.

Change versus previous month

Short interest in ImmunityBio has recently decreased by 0.18%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmunityBio does not currently pay a dividend.

Dividend Growth

ImmunityBio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.63

News Sentiment

ImmunityBio has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for ImmunityBio this week, compared to 9 articles on an average week.

Search Interest

35 people have searched for IBRX on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

27 people have added ImmunityBio to their MarketBeat watchlist in the last 30 days. This is an increase of 575% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImmunityBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

66.10% of the stock of ImmunityBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

8.58% of the stock of ImmunityBio is held by institutions.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IBRX
• CIK: 1326110
• Web: immunitybio.com
• Phone: (844) 696-5235
• Fax: N/A
• Employees: 691
• Year Founded: 2014

Price Target and Rating

• Average Price Target for ImmunityBio: $14.20
• High Price Target: $23.00
• Low Price Target: $9.00
• Potential Upside/Downside: +36.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$351.40 million
• Net Margins: -598.55%
• Pretax Margin: -598.69%
• Return on Equity: N/A
• Return on Assets: -51.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.72
• Quick Ratio: 5.70

Sales & Book Value

• Annual Sales: $113.29 million
• Price / Sales: 97.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.51) per share
• Price / Book: -20.35

Miscellaneous

• Outstanding Shares: 1,059,840,000
• Free Float: 359,284,000
• Market Cap: $11.00 billion
• Optionable: Optionable
• Beta: 0.02